PIPELINE WATCH – Eight Approvals, Five Orphan Designations And One Filing
This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.
You may also be interested in...
Swedish Orphan Biovitrum AB may be in a launch phase with first sales of its long-acting hemophilia products in Europe, but the company is already looking ahead to use its growing commercial capabilities for other products.
New oncology and immunology products are moving rapidly through GSK’s refocused research pipeline, including new agents for multiple myeloma, endometrial and head and neck cancer, adding to efforts against COVID-19, respiratory syncytial virus infection and HIV/AIDS.
GlaxoSmithKline sees initial signs of recovery from the coronavirus pandemic in terms of vaccination rates and highlights its growing research progress against COVID, RSV and meningitis, although a UK expert warns against over-optimism.